Compare ARVN & LWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARVN | LWAY |
|---|---|---|
| Founded | 2015 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 516.2M | 474.0M |
| IPO Year | 2018 | 1995 |
| Metric | ARVN | LWAY |
|---|---|---|
| Price | $8.01 | $30.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 2 |
| Target Price | $15.05 | ★ $34.50 |
| AVG Volume (30 Days) | ★ 647.9K | 181.0K |
| Earning Date | 05-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | 48.33 |
| EPS | N/A | ★ 0.30 |
| Revenue | ★ $262,600,000.00 | $103,350,000.00 |
| Revenue This Year | N/A | $16.64 |
| Revenue Next Year | N/A | $17.28 |
| P/E Ratio | ★ N/A | $101.10 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.06 | $17.31 |
| 52 Week High | $14.22 | $34.20 |
| Indicator | ARVN | LWAY |
|---|---|---|
| Relative Strength Index (RSI) | 42.94 | 57.65 |
| Support Level | $7.90 | $22.03 |
| Resistance Level | $8.90 | $31.23 |
| Average True Range (ATR) | 0.31 | 1.35 |
| MACD | -0.01 | -0.29 |
| Stochastic Oscillator | 6.00 | 58.21 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Lifeway Foods Inc is engaged in manufacturing probiotic, cultured, functional dairy health food products. Its primary product is drinkable kefir, which is a cultured dairy product. Its product categories are Drinkable Kefir, which is the key revenue-driving product, European-style soft cheeses, Cream, ProBugs, Frozen Kefir, and Other dairy. The company manufactures and markets products under the Lifeway and Fresh Made brand names, as well as under private labels on behalf of customers. It sells the products through a direct sales force, brokers, and distributors.